Coronary CT Angiogram: What Your Results Mean and How They Change Your Treatment

What a Coronary CT Angiogram Actually Is

A coronary CT angiogram (CCTA) is a non-invasive imaging study that uses a fast multi-detector CT scanner and an injected iodine-based contrast dye to produce three-dimensional pictures of your coronary arteries. Unlike a calcium score scan, which only counts calcified deposits, CCTA shows both calcified and soft (non-calcified) plaque, the degree to which any plaque narrows the artery lumen, and structural features of the artery wall itself. The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain gives CCTA a Class I, Level of Evidence A recommendation as a front-line test for stable chest pain in patients with an intermediate pre-test probability of obstructive CAD.

The scan typically takes 10-15 minutes. Your heart rate is slowed with a beta-blocker beforehand if it is above roughly 60-65 beats per minute, because motion artifact blurs the images. You will feel the contrast dye as a warm flush through your body. Results come back as a structured report scored by the CAD-RADS (Coronary Artery Disease Reporting and Data System) classification.

How CCTA Differs from a Calcium Score

A coronary artery calcium (CAC) score assigns an Agatston number to calcified plaque only. A score of zero is reassuring, but zero does NOT rule out soft plaque, which can rupture and cause a heart attack even in a young woman with no prior symptoms. CCTA captures both plaque types, making it the more complete picture, especially in premenopausal and perimenopausal women who tend to accumulate non-calcified plaque before calcified plaque becomes detectable as shown in the MESA study.

The CAD-RADS Reporting Scale

| CAD-RADS Score | Stenosis | What It Means | |---|---|---| | 0 | 0% | No plaque seen | | 1 | 1-24% | Minimal, non-obstructive | | 2 | 25-49% | Mild, non-obstructive | | 3 | 50-69% | Moderate, obstructive | | 4A | 70-99% (1-2 vessels) | Severe obstructive | | 4B | 70-99% (left main or 3 vessel) | Severe, high-risk anatomy | | 5 | 100% | Total occlusion | | N | Any | High-risk plaque features noted |

A CAD-RADS 0 or 1 result generally means a very low short-term event risk. CAD-RADS 3 or higher means obstructive disease and triggers the next layer of testing or direct treatment decisions.

Why Women's CCTA Results Are Interpreted Differently

Women develop coronary artery disease differently than men. Full stop. The conventional picture of a man clutching his chest after a 70% left anterior descending artery blockage does not describe most women who have heart attacks. Data from the WISE (Women's Ischemia Syndrome Evaluation) study showed that more than half of women referred for coronary angiography because of chest pain and abnormal stress tests had no obstructive CAD on the catheterization, yet many still experienced major cardiac events over follow-up. This is not a "clean bill of health." It reflects a different disease pattern.

Non-Obstructive Plaque and INOCA

Women are disproportionately affected by ischemia with non-obstructive coronary arteries (INOCA), a condition that includes coronary microvascular dysfunction and coronary vasospasm. A 2023 analysis in the Journal of the American College of Cardiology confirmed that women with INOCA carry a three-fold higher rate of major adverse cardiac events compared with women who have truly normal coronary physiology, even when no stenosis is visible on standard angiography.

CCTA adds value here because it identifies diffuse non-calcified plaque burden that explains microvascular dysfunction even when no single vessel looks obstructed. Finding this changes treatment: your cardiologist may add a statin for plaque stabilization, start aspirin, or investigate coronary microvascular reserve with a stress perfusion study rather than simply reassuring you that your arteries are "fine."

Plaque Type Matters More in Women

High-risk plaque features on CCTA include low-attenuation (soft, lipid-rich) plaque, positive remodeling of the artery wall, spotty calcification, and the napkin-ring sign. The SCOT-HEART trial demonstrated that patients whose management was guided by CCTA had a 41% lower rate of fatal or non-fatal myocardial infarction at five years compared with standard care guided by stress testing alone. That benefit applied across sexes, but the detection advantage was particularly meaningful for women, who were more likely to have their diagnosis missed by functional stress testing alone.

How Your CCTA Result Changes Your Treatment

Your CAD-RADS score is not just a number. It directly maps to a clinical action plan.

CAD-RADS 0 to 1: No or Minimal Plaque

A completely clear scan (CAD-RADS 0) carries an annual major cardiac event rate of well under 1%, allowing most clinicians to defer further cardiac testing for three to five years. The PROMISE trial showed that patients randomized to CCTA-guided evaluation had fewer hospitalizations and lower long-term event rates than those managed with functional testing, partly because a clear CCTA result confidently redirected workup toward non-cardiac causes of chest pain.

If you are a perimenopausal woman with a CAD-RADS 0, this does not mean your risk will stay low indefinitely. Estrogen decline accelerates LDL oxidation and endothelial aging. Your clinician should document your result and re-assess cardiovascular risk factors at menopause or sooner if you develop new symptoms.

CAD-RADS 2: Mild Non-Obstructive Plaque

This finding means plaque exists but does not narrow your artery enough to limit blood flow. Treatment at this stage is usually:

• Statin therapy if you are not already on one, targeting an LDL reduction of at least 30-50%
• High-intensity lifestyle intervention: Mediterranean-pattern diet, 150+ minutes per week of moderate aerobic activity, smoking cessation
• Aspirin only if 10-year ASCVD risk is high enough to justify bleeding risk (your cardiologist calculates this with the AHA Pooled Cohort Equations)
• Annual reassessment of modifiable risk factors

Women with PCOS who reach this finding are often found to have an LDL particle size pattern dominated by small, dense LDL even when total LDL looks normal. A 2022 review in Fertility and Sterility noted that PCOS carries an approximately 1.5-2-fold elevated cardiovascular risk compared with age-matched controls, making early plaque detection especially consequential in this group.

CAD-RADS 3: Moderate Obstructive Stenosis

Stenosis of 50-69% in at least one major vessel is the threshold where blood flow may become restricted under exertion. This result generally triggers:

• Functional stress testing (stress echo, nuclear perfusion, or cardiac MRI) to determine whether the stenosis causes measurable ischemia
• Initiation or intensification of statin therapy, targeting LDL <70 mg/dL for most women with this finding
• Beta-blocker and/or long-acting nitrate if symptoms are present
• Referral to a cardiologist who specializes in ischemic heart disease if not already involved

CAD-RADS 4 and 5: Severe or Total Occlusion

Stenosis at 70% or above in a significant vessel, left main disease, three-vessel disease, or a total occlusion is a serious finding that generally leads to:

• Direct referral for invasive coronary angiography to confirm anatomy and physiology
• Likely percutaneous coronary intervention (PCI, or stenting) or coronary artery bypass grafting (CABG) depending on the anatomy
• Dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor), high-intensity statin, and beta-blocker as a minimum medical regimen
• Urgent same-day evaluation if you have rest pain or unstable symptoms

The 2021 ACC/AHA Guideline on Coronary Artery Revascularization specifies that left main stenosis ≥50% or three-vessel disease with low surgical risk should generally be discussed for revascularization by a multidisciplinary heart team.

High-Risk Plaque Features: The "N" Modifier

Even if your stenosis percentage falls in a lower CAD-RADS category, your report may carry an "N" modifier indicating high-risk plaque features. These include:

• Low-attenuation plaque (lipid-rich core, vulnerable to rupture)
• Positive arterial remodeling (the artery wall expanding outward to hide plaque growth)
• Spotty calcification
• Napkin-ring sign (a halo of low-attenuation tissue around a calcified core)

A 2022 meta-analysis in JACC: Cardiovascular Imaging found that the presence of any high-risk plaque feature on CCTA was associated with a four- to fivefold increase in acute coronary syndrome risk over follow-up, independent of the stenosis grade. If your report carries this modifier, your cardiologist will typically intensify medical therapy regardless of your CAD-RADS number, often escalating to a high-intensity statin and considering ezetimibe or a PCSK9 inhibitor to push LDL below 55 mg/dL.

Life-Stage Guide: CCTA Across a Woman's Reproductive and Hormonal Timeline

Women's cardiovascular risk is not static. Hormonal shifts at each life stage change both the likelihood of finding plaque and the treatment decisions that follow.

Reproductive Years (Ages Roughly 20-40)

Obstructive CAD in a premenopausal woman is uncommon but not impossible, especially with diabetes, familial hypercholesterolemia, lupus, inflammatory bowel disease, or a history of hypertensive disorders of pregnancy. If a CCTA is ordered in a young woman and finds significant plaque, the workup should include screening for autoimmune conditions, thrombophilia, and inherited lipid disorders. Spontaneous coronary artery dissection (SCAD), which predominantly affects women under 50 and often occurs peripartum, has a distinct CCTA appearance: a long, smooth luminal irregularity without discrete atherosclerotic plaque.

Perimenopause (Roughly Ages 45-55)

The menopause transition is a cardiovascular inflection point. The SWAN Heart Study demonstrated that the rate of coronary artery calcification progression accelerated in the years immediately around the final menstrual period, independent of traditional risk factors. Estrogen withdrawal promotes LDL oxidation, increases visceral adiposity, and raises inflammatory markers including CRP and IL-6. A CCTA ordered during this window that shows even mild non-obstructive plaque should prompt aggressive risk-factor modification: optimizing LDL, blood pressure, and blood glucose, and discussing whether menopausal hormone therapy (MHT) is appropriate.

The 2022 Menopause Society (NAMS) position statement notes that MHT initiated within 10 years of menopause or before age 60 (the "timing hypothesis") does not increase cardiovascular events in healthy women and may reduce all-cause mortality. However, MHT is not indicated as a treatment for established CAD. If your CCTA shows significant obstructive plaque, MHT decisions must be made with your cardiologist involved.

Post-Menopause (Ages 55 and Beyond)

After menopause, women's cardiovascular event rates catch up to and eventually exceed men's of the same age, largely because women lose their earlier hormonal protection. Data from the Framingham Heart Study showed that a 50-year-old woman's lifetime risk of developing coronary heart disease was approximately 46%. A CCTA at this stage that reveals obstructive or high-risk plaque triggers the same escalated treatment as in men, but the absolute risk context is different: a 65-year-old postmenopausal woman with a CAD-RADS 3 and elevated hsCRP may benefit from aggressive statin therapy even when her traditional 10-year ASCVD score alone would not have triggered treatment.

What Lowers Your Plaque Burden Over Time

No intervention completely reverses established plaque, but several reduce plaque volume and, more importantly, stabilize vulnerable plaque so it is less likely to rupture.

Statins

High-intensity statins (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) remain the most evidence-backed treatment for plaque stabilization. The ASTEROID trial demonstrated measurable regression of coronary atherosclerosis volume with rosuvastatin 40 mg over 24 months. Women were included in ASTEROID (38% of the cohort) and showed similar plaque volume reduction to men, though women in the trial had lower baseline plaque burden.

Lifestyle Changes That Move the Numbers

• Mediterranean dietary pattern: Associated with 30% lower cardiovascular event rate in the PREDIMED trial (pubmed.ncbi.nlm.nih.gov/23432189)
• Aerobic exercise: 150 minutes per week of moderate-intensity activity reduces coronary plaque progression in intermediate-risk adults
• Smoking cessation: Within one year of quitting, coronary risk falls by roughly 50%
• Weight loss of 5-10% in women with obesity reduces visceral fat, lowers LDL particle count, and decreases endothelial inflammation

PCSK9 Inhibitors

Evolocumab and alirocumab lower LDL by 50-60% on top of statin therapy. The FOURIER trial showed evolocumab reduced major cardiovascular events by 15% over 26 months in high-risk patients. Women represented 24% of the FOURIER cohort, an evidence gap that has been acknowledged by the trial investigators. The benefit in women was directionally consistent but the subgroup was not powered for statistical significance independently.

Pregnancy, Lactation, and Contraception Considerations

CCTA is not routinely performed during pregnancy. The ionizing radiation dose (typically 1-3 mSv with modern dose-reduction protocols, and as low as 0.5 mSv with prospective gating) exposes the fetus to radiation, and the iodinated contrast agent crosses the placental barrier. The American College of Radiology and ACOG Practice Bulletin No. 723 note that fetal radiation exposure from a single thoracic CT study is generally well below the threshold associated with developmental harm (50-100 mSv), but no radiation exposure in pregnancy is considered zero-risk, and CCTA should be deferred unless the clinical question cannot wait, such as suspected acute MI or aortic dissection in a peripartum woman.

If CCTA is performed during lactation, iodinated contrast agents are excreted into breast milk in very small amounts. The ACR Manual on Contrast Media states that the amount of contrast absorbed by an infant from breast milk after a maternal dose is negligible and does not require pumping and discarding milk. Most lactating women can resume breastfeeding immediately after CCTA.

Women of reproductive age who are placed on a statin after a CCTA finding must understand that statins are contraindicated in pregnancy (FDA Pregnancy Category X, now categorized under the PLLR framework as contraindicated based on animal and limited human data showing fetal harm). Reliable contraception is required while on statin therapy if pregnancy is possible. Aspirin in low doses (81 mg) is generally considered compatible with pregnancy after the first trimester under clinical supervision, though high-dose aspirin used for some cardiac indications is not.

If a CCTA reveals findings requiring beta-blockers, note that metoprolol and labetalol are the preferred agents in pregnancy; atenolol is generally avoided due to fetal growth restriction data. PCSK9 inhibitors have no established safety data in pregnancy and should be stopped before conception if possible.

Who Should Consider a CCTA and Who It Is Not Right For

This Test May Be Right for You If:

• You have new stable chest pain or shortness of exertion and an intermediate pre-test probability of CAD (typically a 15-65% estimated risk based on age, symptoms, and risk factors)
• You have a prior inconclusive or uninterpretable stress test
• You are perimenopausal or postmenopausal with multiple risk factors (hypertension, dyslipidemia, diabetes, smoking, family history of premature CAD) and your 10-year ASCVD score sits in the intermediate range (7.5-20%)
• You have a history of hypertensive disorders of pregnancy, preeclampsia, or gestational diabetes, which are now recognized as independent cardiovascular risk factors by ACOG Practice Bulletin
• You have PCOS and are over 40 with additional metabolic risk factors

This Test Is Generally Not Right for You If:

• You have known obstructive CAD already documented on prior catheterization (CCTA adds little beyond what is already known)
• You are in your first or second trimester of pregnancy and the clinical question can wait
• You have severe renal impairment (eGFR <30 mL/min/1.73m²) because the contrast dye poses a nephrotoxicity risk
• You have a documented severe allergy to iodinated contrast
• Your heart rate cannot be adequately controlled below 65 bpm and your anatomy does not allow a prospective-gating protocol

What to Bring to Your Follow-Up Appointment

Your CCTA report will include a narrative description of each major coronary vessel, a CAD-RADS score, notation of any high-risk plaque features, and often a recommendation for the next step. Bring the full report, not just the summary. Ask specifically:

1. What is my CAD-RADS score and what does the plaque type show?
2. Do I have any high-risk plaque features, even if my stenosis is mild?
3. What is my updated 10-year ASCVD risk score incorporating this finding?
4. Does this result change my statin dose or do I need additional lipid-lowering therapy?
5. Should I have a functional stress test as well, and if so, which type is best for my anatomy?
6. When should I repeat imaging or have a follow-up cardiology visit?

The ACC Patient Education library and ACOG's cardiovascular disease in women resources offer readable summaries you can review before your appointment.

Your CCTA result is a map, not a verdict. A CAD-RADS 2 found at age 48 during perimenopause gives you and your care team years to intervene before a blockage becomes obstructive. Start the statin, revise the diet, and schedule the follow-up: the evidence shows those three steps together reduce your five-year event risk by more than any single measure alone.